Prelude Therapeutics (PRLD)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	15.18 mm	15.18 mm	15.18 mm	15.18 mm	15.18 mm	15.18 mm
Cash burn (monthly)	5.56 mm	396.83 k	11.46 mm	11.94 mm	9.10 mm	8.81 mm
Cash used (since last report)	29.46 mm	2.10 mm	60.65 mm	63.19 mm	48.16 mm	46.64 mm
Cash remaining	-14.28 mm	13.08 mm	-45.48 mm	-48.02 mm	-32.98 mm	-31.46 mm
Runway (months of cash)	-2.6	33.0	-4.0	-4.0	-3.6	-3.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

PRLD institutional ownership history Ownership history

72.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	71	62	+14.5%
Opened positions	17	11	+54.5%
Closed positions	8	7	+14.3%
Increased positions	20	15	+33.3%
Reduced positions	20	21	-4.8%

13F shares	Current	Prev Q	Change
Total value	69.03 bn	125.61 bn	-45.0%
Total shares	39.89 mm	38.05 mm	+4.8%
Total puts	300.00	100.00	+200.0%
Total calls	500.00	400.00	+25.0%
Total put/call ratio	0.6	0.3	+140.0%

Largest owners	Shares	Value	Change
Orbimed Advisors	10.91 mm	$22.58 bn	0.0%
Baker Bros. Advisors	10.12 mm	$20.96 bn	0.0%
Flynn James E	4.13 mm	$0.00	0.0%
Deerfield Management	3.77 mm	$7.80 bn	-8.9%
Boxer Capital	1.71 mm	$3.54 bn	-33.5%
T. Rowe Price	1.10 mm	$2.27 mm	+23.1%
BlackRock	1.06 mm	$2.19 bn	NEW
Vanguard	1.02 mm	$2.12 bn	+1.1%
ExodusPoint Capital Management	921.62 k	$1.91 mm	NEW
Avidity Partners Management	890.00 k	$1.84 bn	NEW

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	0.00	-1.07 mm	EXIT
BlackRock	1.06 mm	+1.06 mm	NEW
ExodusPoint Capital Management	921.62 k	+921.62 k	NEW
Avidity Partners Management	890.00 k	+890.00 k	NEW
Boxer Capital	1.71 mm	-860.10 k	-33.5%
Deerfield Management	3.77 mm	-366.88 k	-8.9%
Marshall Wace	359.14 k	+359.14 k	NEW
Sio Capital Management	0.00	-320.39 k	EXIT
T. Rowe Price Investment Management	281.58 k	+281.58 k	NEW
T. Rowe Price	1.10 mm	+206.30 k	+23.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PRLD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
4 Feb 25	Krishna Vaddi	Employee Stock Option Common Stock	Grant	Acquire A	No	No	1.11	496,000	550.56 k	496,000
4 Feb 25	Huang Jane	Employee Stock Option Common Stock	Grant	Acquire A	No	No	1.11	200,000	222.00 k	200,000
4 Feb 25	Andrew Combs	Employee Stock Option Common Stock	Grant	Acquire A	No	No	1.11	175,000	194.25 k	175,000
4 Feb 25	Lim Bryant David	Employee Stock Option Common Stock	Grant	Acquire A	No	No	1.11	200,000	222.00 k	200,000
4 Feb 25	Peggy Scherle	Employee Stock Option Common Stock	Grant	Acquire A	No	No	1.11	175,000	194.25 k	175,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

11 Feb 25

Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

11 Feb 25

JMP Securities Reiterates Market Outperform on Prelude Therapeutics, Lowers Price Target to $4

11 Dec 24

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and lowers the price target from $7 to $4.

Press releases

From Benzinga Pro

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

5 Mar 25

WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

11 Dec 24

• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy • Prelude plans to seek a partner for future development of PRT2527